Product Description
Perphenazine is an old phenothiazine antipsychotic with a potency similar to haloperidol. It has been used for many years and is popular in the northern European countries and Japan. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/25749632/)
Mechanisms of Action: D1 Antagonist,D2 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Canada | Chile | China | Colombia | Denmark | Dominican Republic | Egypt | Finland | Iceland | Ireland | Israel | Italy | Korea | Lebanon | Malaysia | Mexico | New Zealand | Norway | Russia | Singapore | South Africa | Spain | Sweden | Taiwan | Thailand | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: BioLineRx
Company Location: MODI-IN L3 7177871
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Germany
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Brain Damage, Chronic|Brain Death|Hypertension, Pulmonary|Hyperthyroidism|Intracranial Hypertension|Ischemic Stroke|Neuromyelitis Optica
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| REPO-STROKE1 | P1 |
Completed |
Neuromyelitis Optica|Brain Damage, Chronic|Brain Death|Hyperthyroidism|Ischemic Stroke|Hypertension, Pulmonary|Intracranial Hypertension |
2022-02-28 |